AU2021230210A1 - Compound and radioactive labeling compound - Google Patents

Compound and radioactive labeling compound Download PDF

Info

Publication number
AU2021230210A1
AU2021230210A1 AU2021230210A AU2021230210A AU2021230210A1 AU 2021230210 A1 AU2021230210 A1 AU 2021230210A1 AU 2021230210 A AU2021230210 A AU 2021230210A AU 2021230210 A AU2021230210 A AU 2021230210A AU 2021230210 A1 AU2021230210 A1 AU 2021230210A1
Authority
AU
Australia
Prior art keywords
compound
binding moiety
binding
group
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021230210A
Other languages
English (en)
Inventor
Shimpei IIKUNI
Yoshifumi Maya
Masahiro Ono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Kyoto University NUC
Original Assignee
Nihon Medi Physics Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd, Kyoto University NUC filed Critical Nihon Medi Physics Co Ltd
Publication of AU2021230210A1 publication Critical patent/AU2021230210A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021230210A 2020-03-04 2021-03-04 Compound and radioactive labeling compound Pending AU2021230210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-037150 2020-03-04
JP2020037150 2020-03-04
PCT/JP2021/008333 WO2021177390A1 (ja) 2020-03-04 2021-03-04 化合物及び放射性標識化合物

Publications (1)

Publication Number Publication Date
AU2021230210A1 true AU2021230210A1 (en) 2022-09-22

Family

ID=77612690

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021230210A Pending AU2021230210A1 (en) 2020-03-04 2021-03-04 Compound and radioactive labeling compound

Country Status (9)

Country Link
US (1) US20230112418A1 (https=)
EP (1) EP4116306A4 (https=)
JP (1) JPWO2021177390A1 (https=)
KR (1) KR20220148811A (https=)
CN (1) CN115210240A (https=)
AU (1) AU2021230210A1 (https=)
CA (1) CA3174082A1 (https=)
TW (1) TWI908773B (https=)
WO (1) WO2021177390A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
AU2022228911A1 (en) * 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
WO2024249278A2 (en) * 2023-05-26 2024-12-05 Cornell University Macrocyclic chelators and methods of use for the separation of rare earth elements
WO2025189134A1 (en) * 2024-03-08 2025-09-12 ARTBIO, Inc. Methods for treating prostate cancer with radiopharmaceuticals
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物
CN119798110B (zh) * 2025-01-02 2025-09-26 吉林大学 一种4-（对碘苯基）丁基修饰的长循环衣康酸衍生物及制备方法和医用用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102605A1 (en) * 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2760839C (en) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
CN108699108B (zh) 2016-03-01 2022-04-08 国立大学法人千叶大学 放射性标记药物
US10696631B2 (en) 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
MX2019005742A (es) 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
US11167050B2 (en) 2017-09-26 2021-11-09 National University Corporation Chiba University Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound
US20200339625A1 (en) 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
EP3774803A1 (en) * 2018-03-30 2021-02-17 Centre national de la recherche scientifique Pyclen-based macrocyclic ligands, chelates thereof and uses thereof
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MX2021008230A (es) 2019-01-07 2021-08-11 Astellas Pharma Inc Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
CN114364405B (zh) * 2019-04-26 2024-07-16 五一一制药股份有限公司 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂

Also Published As

Publication number Publication date
JPWO2021177390A1 (https=) 2021-09-10
EP4116306A4 (en) 2024-05-29
CA3174082A1 (en) 2021-09-10
CN115210240A (zh) 2022-10-18
US20230112418A1 (en) 2023-04-13
TW202146420A (zh) 2021-12-16
EP4116306A1 (en) 2023-01-11
KR20220148811A (ko) 2022-11-07
TWI908773B (zh) 2025-12-21
WO2021177390A1 (ja) 2021-09-10

Similar Documents

Publication Publication Date Title
AU2021230210A1 (en) Compound and radioactive labeling compound
US9115094B2 (en) Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
EP4303213A1 (en) Compound and radioactive labeling compound
CN104379585B (zh) 18f-标记的叶酸/抗叶酸剂类似物
US10842893B2 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
US9353120B2 (en) Tetraaza macrocyclic compound, preparation method thereof and use thereof
WO2019065774A1 (ja) 放射性薬剤
US10556873B2 (en) Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
Hueting et al. Bis (thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides
Cowley et al. Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu (ATSM)–amino acid] and [Cu (ATSM)–octreotide] conjugates
EP2970154B1 (en) Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
HK40078050A (en) Compound and radioactive labeling compound
KR101253100B1 (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
Bainbridge et al. Synthesis and lanthanum coordination of a BzMacropa analogue for convenient solid-phase peptide synthesis towards targeted alpha therapeutic discovery
TW202428306A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途
WO2025220711A1 (ja) 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
HK40092961A (zh) 化合物及放射性标记化合物
CN116940557A (zh) 化合物及放射性标记化合物
Lodhi Synthesis and In Vivo Biological Evaluation of 99mTc (I) Tri-carbonyl Based Radiopharmaceuticals for SPECT Imaging
CN120590466A (zh) 一种靶向成纤维细胞活化蛋白的化合物及其应用
WO2024051794A1 (zh) 放射性核素偶联药物及其药物组合物和应用
WO2025218677A1 (zh) 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
HK40100289A (zh) 缀合有三接头的二聚体标记前体和由其衍生的放射性示踪剂
CN121175324A (zh) 靶向碳脱氢酶ix的肽结构及其用途
TW202535356A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途